Back to search

Article

CCN5 Activation by free or encapsulated-EGCG is required to Render Triple-negative breast cancer cell Viability and Tumor Progression

2022-03-30

Abstract excerpt

<h4>Background: </h4> and Purpose: Epigallocatechin-3-gallate (EGCG) has been considered an anticancer agent despite conflicting and discrepant bioavailability views. EGCG impairs the viability and self-renewal capacity of triple-negative breast cancer (TNBC) cells and makes them sensitive to estrogen via activating ER-α. Surprisingly, the mechanism of EGCG’s action on TNBC cells remains unclear. CCN5/WISP-2 is a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b17704a5-f180-5a1a-908f-9deb9bb8930d
DOI
10.22541/au.164864795.55156696/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CCN5 Activation by free or encapsulated-EGCG is required to Render Triple-negative breast cancer cell Viability and Tumor ProgressionDOI 10.22541/au.164864795.55156696/v1
Select a neighboring publication to make it the new centre.